Funding awarded

  • QR Laboratories, Athens, Greece, private donation: 12.000 euros / month,
    2024-2029.
  • Applied Research for Precision Medicine through a Non-Profit Organisation (NPO) under Private Law – “Hellenic Precision Medicine Network ” (ΗPMN), 200.000 euros, 2023-2025.
  • COST funding: “SENESCENCE2030: Targeting Cell Senescence to Prevent Age-Related Diseases”, code OC-2023-1-26592, 2024-2028.
  • “Our first steps to Europe: Pleistocene Homo sapiens dispersals, adaptations and interactions in South-East Europe” (FIRSTSTEPS), European Research Council (ERC) AdGn, 2.500.000 euros, Collaborating PI, 2022-2026
  • Sonia & Nikos Kotopoulos Trust/Medi Jeunesse, New Jersey, USA, private donation: 55.000 euros, 2022
  • “Centre of Innovative Electron Microscopy Applications and Services of NKUA” Funded by GSRT with 1.500.000 euros, HFRI code HFRI-FM17C3-2906, 2021-2023
  • “Application of artificial intelligence for the development of drugs and new therapies” Flagship Initiative funded by the National Public Investment Program of the Ministry of Development and Investment / General Secretariat for Research and Innovation (2020ΣΜ01300002), 1.500.000 euros, 2021-2025, in collaboration with Intelligencia.
  • “Emblematic action to handle SARS-CoV-2 infection: Epidemiological study in Greece via extensive testing for viral and antibody detection, sequencing of the virome and genetic analysis of the carriers” Funded by GSRT No 2020ΣΕ01300001, 2.500.000 euros, 2020-2022
  • “Revealing senescent cells with novel and innovative compounds” Funded by GSRT with 509.568,02 euros, “EPAnEK” program, 2020-2023
  • “MRC iCASE Leadership, University of Manchester, UK, 100.000 £, 2020-2023”
  • “Interrogating the Pathophysiological Consequences of deregulated Replication Licensing” Funded by GSRT with 180.000 euros, HFRI code 3782, 2020-2023
  • Harris Pappas private donation: years 2020-2021; total budget: 100.000$ (in collaboration with Prof CJ Logothetis, MD Anderson Cancer Center, Texas)
  • “NIHR i4i-connect”, DeepMed in collaboration with University of Manchester, UK, 150.000 £, 2019
  • “Deep Learning powered Metastases Detection System for Digital Pathology”, Funded by Small Business Research Initiative (SBRI) Healthcare Challenge on Cancer του NHS UK with1.000.000 £, 2019
  • “Hippo pathway in genome and epigenome maintenance” Funded by GSRT with 180.000 euros, HFRI code 775, 2018-2021
  • “Revealing senescent cells with novel and innovative compounds” Funded by GSRT with 998.340 Euros, “EPAnEK” program, 2018-2021
  • KIKPE Foundation (www.kikpe.gr): years 2018-2021; total budget: 150.000$ (in collaboration with Prof CJ Logothetis, MD Anderson Cancer Center, Texas)
  • AstraZeneca: year 2018; total budget: 22.000€
  • “Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network (SYNTRAIN)”, Innovative Training Networks (ITN), Funded by EC, Horizon 2020, with 227987 Euros, Project code 722729, 2016-2020
  • Thomas Helledays Foundation for Medical Research, Sweden: years 2017-2018; total budget: 20.000€
  • IKY-Simens Excellence (Aristeia) 2016 grant application
  • DHI Global Medical Group: year 2016; total budget: 35.000€
  • Marousis AE (Covidien): year 2016; total budget: 2.000€
  • “Transcriptional reprogramming features triggered by oncogenic Cdc6” Funded by the GSRT with 200.000 Euros, “ARISTEIA II” program, project code 3020, 2014-2015
  • “INtegrating the emerging research Potential of the University of Athens Cancer Research Group in the European research area (INsPiRE)”, Funded by EC, FP7, with 2.500.000 Euros, Project code 284460, 2011-2014
  • ELPEN: years 2011-2012 and 2015-2016; total budget: 30.000€
  • Hollister Hellas S.A.: year 2011; total budget: 2.000€
  • Roche Hellas S.A.: year: 2009; total budget: 20.000€
  • “Inflammation and Cancer (INFLA-CARE)” Funded by EC, FP7, with 380.000 Euros, 2008-2010
  • “Genomic Instability in Cancer and Precancer (GENICA)” Funded by EC, FP7 with 360.000 Euros, project code 201630, 2008-2010
  • GENESIS Pharma S.A.: year: 2008; total budget: 20.000€
  • Pfizer Hellas S.A.: year 2008; total budget: 1.000€
  • Novartis Hellas S.A.: years 2007 – 2009; total budget: 21.000€
  • “Gene therapy in Cystic Fibrosis: Expression of CFTR gene by human artificial chromosomes” Funded by GSRT with 78.000 Euros, “ENTER” prorgam, project code SARG 70/3/8660, 2006-2007
  • “Study of the changes in the genetic locus KIP2/CDKN1C and its expression in Non-Small Cell Lung Cancer” Funded by the GSRT with 100.000 Euros, “Pythagoras II” program, project code: 70/3/7953 SARG, 2005-2006
  • “Study of the effect of genotoxic agents on the survival of colon cancer cell lines, emphasis on the E2F1–dependent apoptosis” Funded by the GSRT with 100.000 Euros, “Pythagoras II” program, project code 70/3/7952 SARG, 2005-2006
  • Wyeth Hellas S.A.: year 2006 – 2007; total budget: 5.000€
  • “Sensitivity of cancer cells to chemotherapeutic drugs affecting the microtubule integrity: molecular mechanisms related to the expression of the oncosuppressive protein p53 and the oncogene c-mos” Funded by the GSRT with 30.000 Euros, “Heraklitos” program, project code 70/3/7211, 2005
  • “Investigation of the E2F-1 induced p73-dependent apoptosis in colon cancer after DNA damage”. Funded with 3509$, by UICC, code ICRETT No998, March – July 2004
  • “Study of the E2F family of transcriptional factors in the commonest malignancies” Funded with 100.000 Euros by the GSRT, “Pythagoras” program, project code: 20.2.04/10856, 2004
  • “Study of the deregulation of DNA licensing factors, the activation of DNA damage response and their relation with kinetic parameters and ploidy in Non-Small Cell Lung Cancer” Funded by GSRT with 138.480 Euros, “PENED 2003” program, project code 5325/10.05.2004
  • “Carcinogenesis in the respiratory system. Defects in the signaling pathways” Funded by the GSRT, “Kapodistrias” program, project code 70/4/4281, 4.000 euros, 2003
  • “Carcinogenesis in the respiratory system. Defects in cell adhesion mechanisms” Funded by the GSRT, “Kapodistrias” program, project code 70/4/4591, 4.000 euros, 2003
  • “Improvement of Prevention Diagnosis and Treatment of sarcoidosis and Crohn’s disease (SACROHN)”. Funded by the EC, Framework Program 5, with 250.000 Euros, 2000-2002, SARG-NKUA project code 70/3/5394. Co-Investigator
  • “The role of mutant p53 in disturbing the negative feedback mechanism p53-MDM2 in lung cancer” Funded by GSRT with 5.000.000 drachmas, Activity 2.2, Call ΥΠΕΡ97, Project code 97ΥΠ218, July 1998 – March 2001
  • “Cancer Biology: gene analysis and in vivo imaging of receptors – radiotherapy” Funded by the Framework Program Research and Technology (FPRT) II, Activity 1.2, GSRT, Project code: 97 ΕΚΒΑΝ2-112, 1-9-1998 – 31-8-2001. Funded by the GSRT with 17.000.000 drachmas
  • “Improvement of Salmonella control in animal feeds based on the molecular and biochemical analysis of the product” funded by EC, FP4 through the CRAFT mechanism, with 500.000 drachmas, 1997
  • “Carcinogenesis in the upper and lower respiratory system”. Funded by the National Board of Health with 50.000 drachmas, 1996-1997
  • “Molecular Genetics: a. national registry for inheritable diseases in Greece, training of the medical and nursing staff, b. use of molecular biology techniques for the recognition of the responsible gene for the inheritable colon adenocarcinoma”. Funded by the Special Account for Research Grants (SARG) with 500.000 drachmas, 1997
  • “Breast carcinogenesis”. Funded by the National Board of Health with 5.000.000 drachmas, 1996
Search